share_log

【港股通】再鼎医药(09688):奥凯乐获批用于治疗ROS1阳性非小细胞肺癌

[Hong Kong Stock Connect] Zaiding Pharmaceutical (09688): Okella approved for the treatment of ROS1-positive non-small cell lung cancer

金吾財訊 ·  May 12 20:54

Jinwu Financial News | Zaiding Pharmaceutical (09688) announced that Okela (reptinib) has been approved by the China National Drug Administration to treat adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer.

Okela (reptinib) is a new generation tyrosine kinase inhibitor targeting ROS1 and NTRK carcinogenic factors. The company entered into an exclusive license agreement with Turning Point Therapeutics, Inc. (a wholly-owned subsidiary of Bristol-Myers Squibb) to develop and commercialize reptinib in mainland China (mainland), Hong Kong, and Macau.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment